Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory...
– LINZESS® (linaclotide) U.S. net sales of $273 million in Q1 2026, primarily driven by improved net price and 5% EUTRx demand growth year-over-year – – Total revenue...
Barchart Research What to Expect from IRWD Earnings IRWD Generated May 6, 2026 Current Price $4.83 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 13.83% Ironwood's Revenue Guidance Looks...
– Surveyed HCPs identified reduction of days on TPN as a top priority – – Improved quality of life, lower risk of infection and thrombosis viewed as key benefits...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026....
– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) – ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11 th ...
– LINZESS ® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP...